

Simulated Microgravity Regulates Gene transcript Profiles of 2T3 Preosteoblasts : Comparison of the Random Positioning Machine and the Rotating Wall Vessel Bioreactor

Mamta J. Patel^{1,2}, Wenbin Liu³, Michelle C. Sykes¹, Nancy E. Ward², Semyon A. Risin⁴, Diana Risin², Hanjoong Jo^{1,5,¶}

1) Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, Georgia 30322; 2) Space Life Sciences Directorate, Human Adaptation and Countermeasures Office, NASA/Johnson Space Center, Houston, Texas 77058; 3) Department of Molecular and Human Genetics and Microarray Core Facility, Baylor College of Medicine, Houston, Texas 77030; 4) Department of Pathology and Laboratory Medicine, University of Texas-Houston Medical School, Houston, Texas 77030; 5) Division of Cardiology, Emory University School of Medicine, Atlanta, Georgia 30322;

¶ To whom correspondence should be addressed: Hanjoong Jo, Ph.D., Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University, 2005 WMB, Atlanta, GA 30322. Tel.: 404-712-9654; FAX: 404-727-3330; E-mail: hanjoong.jo@bme.gatech.edu

Running Title: Microgravity sensitive genes in osteoblasts

Abstract

Microgravity of spaceflight induces bone loss due in part to decreased bone formation by osteoblasts. We have previously examined the microgravity-induced changes in gene expression profiles in 2T3 preosteoblasts using the Random Positioning Machine (RPM) to simulate microgravity conditions. Here, we hypothesized that exposure of preosteoblasts to an independent microgravity simulator, the Rotating Wall Vessel (RWV), induces similar changes in differentiation and gene transcript profiles, resulting in a more confined list of gravi-sensitive genes that may play a role in bone formation. In comparison to static 1g controls, exposure of 2T3 cells to RWV for 3 days inhibited alkaline phosphatase activity, a marker of differentiation, and downregulated 61 genes and upregulated 45 genes by more than two-fold as shown by microarray analysis. The microarray results were confirmed with real time PCR for downregulated genes *osteomodulin*, *bone morphogenic protein 4 (BMP4)*, *runx2*, and *parathyroid hormone receptor 1*. Western blot analysis validated the expression of three downregulated genes, *BMP4*, *peroxiredoxin IV*, and *osteoglycin*, and one upregulated gene *peroxiredoxin I*. Comparison of the microarrays from the RPM and the RWV studies identified 14 gravi-sensitive genes that changed in the same direction in both systems. Further comparison of our results to a published database showing gene transcript profiles of mechanically loaded mouse tibiae revealed 16 genes upregulated by the loading that were shown to be downregulated by RWV and RPM. These mechanosensitive genes identified by the comparative studies may provide novel insights into understanding the mechanisms regulating bone formation and potential targets of countermeasure against decreased bone formation both in astronauts and in general patients with musculoskeletal disorders.

Key Words: bone formation, alkaline phosphatase, RWV, RPM, microgravity, osteoblasts

Introduction

Exposure to microgravity conditions during spaceflights induces several adaptive and pathophysiological changes to the human body, posing health risks to astronauts during space flights. These pathophysiological changes include reduced cardiovascular performance (1, 2), immune system dysfunction (3), skeletal muscle atrophy (4, 5), bone demineralization (6-9), decreased bone mass (10-13), and increased bone resorption (13, 14). Astronauts lose bone mass as much as 1%-2% per month during spaceflight, and this may be due to either decreasing bone formation by osteoblasts or increasing osteolytic functions of osteoclasts (6, 14). Many of the known space-inflicted pathologies have been the subject of research, and the bone loss has not been adequately counteracted with dietary supplements (12, 15, 16) or rigorous exercise (4). This is due in part to the lack of understanding of the mechanisms leading to the effects of microgravity on bone cells.

While it would be ideal to conduct studies to discover the mechanisms in real microgravity conditions, it has become extremely difficult, rare, expensive, and impractical to most investigators. As an alternative, and a complementary means in some cases, investigators have developed ground-based systems to simulate microgravity conditions on Earth (17-20). Simulated microgravity is based on the hypothesis that sensing no weight would have similar effects as being weightless (21). The 1D and 3D clinostats such as the Rotating Wall Vessel bioreactor (RWV) and the Random Positioning Machine (RPM) simulate microgravity by continuously moving the gravity vector, a method called gravity-vector averaging, yielding a net-zero sum of gravity vectors averaged over time. The key aspect in gravity-vector averaging is that the movement of the gravity vector must be faster than the cell sensors can detect gravity (19).

For the microgravity simulators to be used widely and accepted as valid model systems to study microgravity effects on human biology, the biological and pathophysiological effects of each simulator should be compared to each other and, if possible, to real microgravity conditions. There is one comparison between the RPM and the RWV in which cell proliferation and cytoskeletal organization were evaluated in endothelial cells exposed to both simulators (22). However, detailed experiments assessing biological function and genetic changes were not performed, and there was no discussion relating the observed changes to microgravity-induced pathologies. However, as far as we are aware, no unbiased comparison amongst the various microgravity simulators as related to bone loss studies has been reported.

Recently, we have characterized gene transcript expression profiles of 10,000 genes using Codelink gene chips in 2T3 murine pre-osteoblasts exposed to RPM-simulated microgravity conditions (20). We compiled a list of 140 genes (gravi-sensitive genes) that changed in response to the simulated microgravity conditions with the RPM, and some of them may be involved in decreased bone formation. In contrast, Xing et al, have characterized gene transcript profile changes induced by exposing mouse tibia to mechanical stimulation, an apparent opposite of microgravity conditions, using a four-point bending method (23). Therefore, we hypothesized that simulated microgravity using the RWV inhibits differentiation and alters gene expression profiles of 2T3 pre-osteoblasts, recapitulating the trends produced by the RPM, while inducing the opposite trends produced by mechanical stimulation of bones. To test this hypothesis, we carried out an additional gene transcript profiling study with 2T3 cells exposed to the NASA developed RWV, and compared the results to our previous transcript database obtained with the RPM. In addition, we compared both the RWV and RPM transcript databases to the database obtained from the mechanically loaded mouse tibias (23). From these studies, we found 16

genes that were affected in all three studies, suggesting that they may be implicated in microgravity-induced decrease in bone formation.

Results

RWV-simulated microgravity inhibits alkaline phosphatase activity.

Expression of alkaline phosphatase (ALP) increases as osteoblasts mature and differentiate, and its enzyme activity is often used as a marker for bone formation. Thus, we chose to examine the effects of RWV-simulated microgravity on ALP enzyme activity in pre-osteoblasts. As shown in Figure 2, exposure of cells to the RWV for 3 days significantly decreased ALP mRNA (Panel A) and its activity (Panel B) by 3-fold in comparison to static 1g controls. This finding, which is consistent to our previously reported data with the RPM (20), suggests that the simulated microgravity conditions induced by either the RWV or the RPM results in the similar inhibitory effect on osteoblast differentiation.

RWV-simulated microgravity alters gene expression profiles of 2T3 cells as determined by microarray studies.

DNA microarray studies were performed on samples obtained from 2T3 cells exposed to the static 1g or RWV-simulated microgravity for 3 days. Among approximately 40,000 genes tested by the Affymetrix array, 61 were downregulated while 43 were upregulated statistically significantly by more than two fold above the static 1g control ($p < 0.05$) as shown in a scatter plot of the genes (Figure 3). Table 1 shows a subset of these genes organized by biological process as defined by GoMiner, and each gene is given an associated molecular function where available. Additionally, Table 2 provides a list of genes from the microarray that may be implicated in bone

formation or mineralization as determined by literature survey, and these genes are organized by fold change with molecular function when known. The entire array can be accessed from Gene Expression Omnibus (GEO).

Validation of the microarray data with the quantitative Real Time-PCR and immunoblotting.

To confirm our microarray data, we performed real time PCR and Western blot analyses for a select subset of genes that may be implicated in bone formation. The same samples that were used for the microarrays were used for the real time-PCR, and additional RWV experiments were performed to obtain protein samples for the Western blots. The 2T3 cells exposed to RWV had decreases in *runx related transcription factor 2 (Runx2)*, *bone morphogenic protein 4 (BMP4)*, *parathyroid hormone receptor 1 (PthR1)*, and *osteomodulin (Omd)* gene expression by a fold change of 0.69, 0.40, 0.54, and 0.10, respectively, as evaluated by the Affymetrix microarray. The gene expression fold changes by real time PCR for *Runx2*, *BMP4*, *PthR1*, and *Omd*, were 0.38, 0.26, 0.59, and 0.10, respectively (Figure 4 A-E). Additionally, we confirmed the expression of downregulated genes *BMP4*, *peroxiredoxin IV (PrxIV)*, and *osteoglycin (Ogn)* and upregulated gene *peroxiredoxin I (PrxI)* by immunoblotting. The Affymetrix fold changes for *BMP4*, *PrxIV*, *Ogn*, and *PrxI* were 0.40, 0.62, 0.23, and 1.23. We showed that the fold changes for these genes by Western blot were 0.59, 0.68, 0.32, and 1.58, respectively (Figure 4 F-J). The different methodologies used, real time PCR, immunoblotting, and the microarray assay, produced highly consistent results, providing a level of assurance regarding the validity of the microarray data.

Comparison of the RPM and RWV microarrays reveals 14 genes that changed in the same way.

There was a subset of genes that demonstrated similar expression changes when exposed to simulated microgravity in both the RPM and RWV experiments. Table 3 displays those genes that changed statistically significantly with $p < 0.05$. There were 13 downregulated genes and 1 upregulated gene in this group. With such a small sample size ($n=3$), we felt it was valuable to evaluate which genes changed commonly in both simulators with less stringent p-value cutoffs. Under this non-stringent condition, there were also 11 downregulated and 5 upregulated genes whose change in expression did not reach statistical significance ($0.05 < p < 0.1$) but changed in the same direction with exposure to both simulators (data not shown). Table 3 organizes the significant genes by biological process as defined by GoMiner and associates each gene with a molecular function, if known. Interestingly, many of the genes in both tables have been implicated in skeletal remodeling, including *fibromodulin*, *osteomodulin*, and *osteoglycin* (24-26).

Comparison of microgravity microarrays to a mechanical loading microarray produced a list of 16 genes that changed in opposite directions between microgravity and mechanical loading.

Recently, Xing, et al. published their microarray data on mice that were mechanically loaded (23). Briefly, they loaded mice in a four point bending mechanical device for four days and total RNA was obtained from the region of the mechanically stimulated tibia. The untreated tibias of the same mice were used as unloaded controls. They used a 22,000 gene Agilent Technologies microarray (23). We compared our RPM and RWV microarrays to their published

data and compiled an interesting list of common genes changing in opposite directions. Sixteen genes that were upregulated by loading were downregulated in the cells exposed to simulated microgravity conditions by the RPM and RWV (Table 4). Table 4 compares the fold changes for the RWV, RPM, and mechanically-loaded mouse tibias. There were many genes that were altered by loading and microgravity that are believed to play roles in bone remodeling, including *pleiotrophin*, *legumain*, and *follistatin* (27-31).

Discussion

We have previously developed an *in vitro* method combining the 3D-clinostat RPM and 2T3 pre-osteoblasts cells cultured in tissue culture disks called Opticells, in which the cells are encapsulated by two polystyrene, gas-permeable membranes to which the cells are adhered (20). The RPM-simulated microgravity significantly inhibited alkaline phosphatase activity over a time course of 9 days, without significantly altering cell morphology or cell proliferation (20). Additionally, using gene microarrays scanning 10,000 mouse genes, we produced a list of 52 upregulated and 88 downregulated genes by more than two-fold above the static 1g control with statistical significance ($p < 0.05$).

Here, we used another approach to expose the adherent 2T3 cells to simulated microgravity using the 1-D clinostat RWV bioreactor, which maintains constant suspension of the cells. Unlike the RPM system where the cells were attached to OptiCell membranes and exposed to simulated microgravity, the RWV does not have a similar platform so the adherent cells had to be grown on microcarriers for exposure to RWV-simulated microgravity. To compare the results of the RWV to those published with the RPM, we aimed to control the experimental conditions as much as possible. We used the same seeding density of 10,000

cells/cm², and we chose a microcarrier that had the most similarity to the Opticell membrane, which was used in the RPM studies. In our previous RPM studies, 2T3 cells grew well on the OptiCells without requiring any extracellular matrix other than what was available from fetal bovine serum contained in the cell culture medium. Therefore, we used the same culture conditions to grow 2T3 cells on the microcarriers and found no difference in cell growth and morphological characteristics (data not shown). Under this condition, we found that cells adhered to the microcarriers with 80% efficiency (n=9) within a day as determined by cell counting. Most importantly, we independently confirmed the RPM data showing that the RWV produced similar results regarding cell differentiation, as determined by alkaline phosphatase (*ALP*) enzyme activity. These results suggest that the RPM and RWV exposures inhibit cell differentiation of pre-osteoblasts, a finding that seems to be consistent with the microgravity-induced bone loss response.

Previously, it has been controversial whether RWV-simulated microgravity decreases or increases *ALP* activity, but this may be due to a difference of whether the cells were grown as attached vs. suspended cells. Rucci, et. al. found that *ALP* activity and mRNA expression increased when exposed to the RWV for 2 days using the rat osteoblast-like cell line that was grown as a suspension, which then formed aggregates (32). In contrast, Klement, et al. showed that exposure to the RWV for up to 14 days blunted *ALP* activity and bone matrix mineralization of mouse embryonic pre-metatarsal tissue explants(18). It should be noted that in this condition the bone cells were still attached on the extracellular matrix within the embryonic bone tissues. In our current and the previous study, the pre-osteoblasts were grown as adherent cells either on microcarriers or on the OptiCell membranes before and during exposure to the RPM or RWV. These results suggest that the inhibitory effect of the RWV and RPM on the osteoblastic function

requires the bone cells grown as adherent cells during the exposure to the simulated microgravity. Additionally, our finding partially validates and supports the use of ground-based simulators to study microgravity-induced changes in bone cell biology and pathophysiology.

We also performed gene microarray analysis to determine changes in gene expression profiles of the pre-osteoblasts and compared the results to our published findings with the RPM. We found that 14 genes changed in the same way, and many of these genes are involved in skeletal remodeling. For example, we confirmed expression levels of *runx2*, which was downregulated by approximately 1.5-fold and is believed to be a “master gene” that plays a critical role in the formation of the skeleton. When *Runx2* is genetically knocked out in a mouse model, there is a complete lack of skeleton formation (33, 34). Additionally, *asporin* (*Aspn*) and *proline arginine-rich end leucine-rich repeat* protein (*PRELP*) were both downregulated by simulated microgravity in both the RWV and RPM by 3.5 and 2.2-fold, respectively. *Asporin* is a cartilage extracellular protein and a member of the well known family of secreted proteoglycans present in many connective tissues called small leucine rich proteoglycans (SLRPs) (35, 36). *Aspn* is known to regulate the activity of transforming growth factor-beta (TGF β) and forms an association with *calmodulin 1* (*Calml*), which is an intracellular protein that interacts with a number of proteins involved in signal transduction. The association of *Aspn* and *Calml* reduces the ability of chondrocytes to make aggrecan and type II collagen (35). Aggrecan and type II collagen are essential constituents of articular cartilage, and collagen abnormalities are associated with skeletal abnormalities (35). *PRELP* is categorized by GoMiner to be involved in skeletal development and has been found to bind collagen type I and type II through its leucine-rich repeat domain (37). A decrease in *parathyroid hormone related protein*, which plays a role in calcium mobilization, has been linked to decreases in bone density and

subsequent bone loss in space-flown rats (38). This is consistent with the decrease in the *parathyroid hormone receptor 1* levels by simulated microgravity, which was confirmed by RT-PCR. *Osteomodulin* belongs to the SLRP family and may be involved in bone matrix formation (25), and simulated microgravity-induced decrease in *Omd* is consistent with our hypothesis.

Additionally, we confirmed the downregulated expression levels of *bone morphogenic protein 4 (BMP4)*, a member of the bone morphogenic protein (BMP) family, and *BMP4* is involved in skeleton development, including cartilage formation and various joint developments (39, 40). Moreover, oxidative stress is involved in the etiology of various pathologies, and oxidants are produced under physiological conditions during phagocytosis by macrophages, mitochondrial electron transport, and bone resorption by osteoclasts (41). Bone resorption is known to increase beyond normal physiological levels in spaceflight (14), potentially increasing the levels of oxidative stress in the human body. Oxidative stress can lead to breaks in DNA, depletion of cellular energy stores, and cell death, and oxidants play important roles in cell signaling (41). Peroxiredoxins are a family of antioxidants that are often made by cells in response to oxidant production. It has been found that *peroxiredoxin I* is upregulated during bone cell differentiation (41, 42). We found that *PrxI* was upregulated while *peroxiredoxin IV* was downregulated by RWV-simulated microgravity, suggesting that the cells may be responding to oxidative stress agents and trying to compensate for these changes. Moreover, from Table 1, there is a large group of genes involved in cell adhesion that changes upon exposure to simulated microgravity. In general, with the exception of *procollagen XI*, several of these genes that were upregulated are extracellular matrix proteins such as *procollagen IV* and *integrin alpha 6*. There also were several genes involved in cytoskeletal regulation that changed, such as *tubulin*. It also seems that heat shock proteins involved in protein folding change upon

exposure to simulated microgravity. These results indicate possible candidate genes involved in decreased bone formation in astronauts, suggesting that this decrease is related to changes in the expression of genes necessary for osteoblast differentiation, matrix formation, subsequent mineralization, and cartilage maintenance.

To further investigate the functional significance of the microgravity-associated changes in gene expression, we compared our microarray results to independently published data from mechanically loaded tibias in a mouse model (23). When we compared their gene chip results to those of the RPM and RWV microarrays, we found 16 genes that were upregulated by mechanical loading and contrastingly downregulated by simulated microgravity. Moreover, many of these genes are highly involved in bone remodeling. For example, *pleiotrophin* and *osteoglycin* were not only downregulated by simulated microgravity but also upregulated by mechanical loading. *Pleiotrophin* has been found to be involved in early bone development and osteoblast function (27). Overexpression of *pleiotrophin* in mice enhances bone growth early in development, but its effects diminish over time (27). However, the *pleiotrophin* knockout mouse does not have an altered bone remodeling phenotype (28). *Pleiotrophin* is synthesized by osteoblasts at an early stage of differentiation, and the gene is present at new sites of bone formation (29). *Osteoglycin* is a small leucine-rich proteoglycan found in the extracellular matrix of bone, and knockout mice for this gene display collagen fibril diameter abnormalities (24). Additionally, *legumain* has been identified as an inhibitor of osteoclast function and thus bone resorption (30). Simulated microgravity by the RPM and RWV downregulated this inhibitor with fold changes of 0.66 and 0.64, respectively, while loading upregulated *legumain* by 3.3-fold, suggesting that microgravity may induce expression of genes normally involved in bone resorption. Disruption of the tight coupling between bone formation and bone resorption

has been recognized as a general mechanism inducing bone loss (43, 44). Microgravity-induced alteration of genes like *legumain* is consistent with this notion. These comparisons suggest that a subset of these gravity-sensitive genes is also mechanical load-sensitive and may be implicated in microgravity-induced decreased bone formation. Spaceflight is characterized as an environment in which the human body is no longer loaded as on Earth. Therefore, it is interesting that many genes that are changed by loading are also changed in the opposite direction by “unloading”, or simulated microgravity.

In conclusion, we have shown that the two different simulators of microgravity produce similar results with regard to bone cell differentiation and osteoblast function. We have shown by alkaline phosphatase activity that both simulators reproduce a decreased bone formation response as also seen in spaceflight. Furthermore, we have compiled a confined list of genes that change in response to the two different types of simulated microgravity conditions and to mechanical loading, which could provide a limited number of specific targets for interventions to cure or prevent bone loss not only in astronauts but also in patients on Earth with various metabolic musculoskeletal diseases.

Materials and Methods

Cell culture—2T3 murine osteoblast precursor cells were cultured in MEM [α -minimal essential medium containing 10% fetal bovine serum (Atlanta Biologicals) with 100 U/ml penicillin and 100 μ g/ml streptomycin] in a standard humidified incubator (37°C, 5% CO₂) as described by us previously (20). For RWV experiments, trypsinized cells were seeded on microcarriers (#P102-1521, Solohill, Ann Arbor, MI), which has a polystyrene core with no extracellular matrix coating. Microbeads, needed to obtain 100cm² surface growth area based on the surface area of

each bead, were prepared in sterile PBS (50mg/ml) and autoclaved as suggested by the manufacturer. We plated 1 million cells with 5.6 grams of beads in a low adhesion 100mm plate (Corning, Inc. #3262) so that the cells adhered to the beads and not the plate. The cells were allowed to grow for 3 days to confluency and then transferred to a RWV with approximately 55ml of culture media. Media bubbles were removed with a two-syringe system. For static 1g control, cells were kept in the same incubator in the low adhesion plate with the identical media for the matching experimental duration as the RWV group.

Rotating Wall Vessel (RWV)— Rotation of the RWV (Figure 1) maintains microbeads attached with 2T3 pre-osteoblasts in a continuous free-fall state, simulating a microgravity environment (45). The RWV is rotated in a single mode, and the rate of rotation varies according to cell type, microcarrier density, and number of cell-bead aggregates. For our experiments, we rotated the RWV at 22 RPMs (rotations/minute). Over three days of RWV exposure, the rotation rate did not need to be altered as the cell-bead aggregates maintained suspension. Figure 1-B shows the RPM (20) as a comparison.

Whole cell lysate and alkaline phosphatase enzyme activity—Following the RWV or static 1g exposure, cells and beads were washed with cold PBS 2 times and lysed in 500 μ l of a lysis buffer containing 0.1% Triton X-100 in 1mM $MgCl_2$, 20mM Tris-HCl, and 0.1mM $ZnCl_2$. The lysate and bead mixture was centrifuged for 3-5 minutes at 1,500 rpm to separate the beads from the lysate. The lysate was pipetted out of the mixture and stored at $-20^{\circ}C$ until needed. Protein assay using the Bio-Rad DC protein assay and the alkaline phosphatase activity using a Diagnostics ALP assay kit (Sigma) were carried out as we described previously (20).

Immunoblotting—Aliquots of cell lysates (20 µg protein) were resolved on a SDS-PAGE gel and transferred to a polyvinylidene difluoride membrane (Millipore) (46). The membrane was incubated with a primary antibody overnight at 4°C and then incubated with a secondary antibody conjugated with alkaline phosphatase for 1 h at room temperature. Expression was detected by a chemiluminescence method and the intensities of immunoreactive bands were determined by densitometry (46). A polyclonal primary antibody for BMP4 (Santa Cruz Biotechnologies), osteoglycin (R&D Biosciences), and polyclonal antibodies for peroxiredoxin I and peroxiredoxin IV (Lab Frontier, Seoul, Korea) were used for these studies.

RNA isolation—Total RNA was prepared by using the RNeasy Mini kit (Qiagen). Briefly, after two cold PBS washes, 500µl of RLT lysis buffer containing β-mercaptoethanol was added to the bead and cell mixture to isolate the RNA from the beads and cells. The bead and lysate mixture was centrifuged for 3 minutes at 1,500 RPMs to separate the beads from the RNA, and the RNA was pipetted to the homogenizing column in the RNeasy kit. The RNA was purified with the kit and stored at –80°C until needed.

Reverse Transcriptase and Real-Time Polymerase Chain Reaction— Total RNA was reverse transcribed by using random primers and a Superscript-II kit (Life Technology) (47). The synthesized and purified cDNA was amplified using a LightCycler (Roche Applied Science), and the size of each PCR product was verified by agarose gel electrophoresis as described by us (47). The mRNA copy numbers were determined based on standard curves generated with the genes of interest and 18S templates. The 18S primers (50 nM at 61°C annealing temperature; Ambion)

were used as an internal control for real-time PCR using capillaries (Roche Applied Science), recombinant Taq polymerase (Invitrogen), and Taq start antibody (Clontech). The primer pairs for the quantitative real-time PCR are listed in Table 5 along with Light Cycler conditions. Real-time PCR for the listed genes were carried out in PCR buffer (20mM Tris-Cl, pH 8.4 at 25°C, 4mM MgCl₂, 250 µg/ml bovine serum albumin, and 200 µM deoxynucleotides) containing SYBR green (1:84,000 dilution), 0.05unit/µl Taq DNA polymerase, and Taq Start antibody (1:100 dilution) as described previously by us (47).

Affymetrix Gene Microarrays— All RNA samples passed the microarray test for RNA quality and concentration before proceeding to the gene chip study carried out in the Microarray Core Facility at the Baylor College of Medicine. The array used was Affymetrix GeneChip® Mouse 430 2.0, and the data were background adjusted and normalized to median intensity. The data were transformed so that fold changes were obtained by dividing the averaged normalized intensities of the microgravity samples by the averaged normalized intensities of the static samples. Thus, a fold change above 1 indicates a gene upregulated by simulated microgravity and below 1 indicates a gene downregulated by simulated microgravity. The data were statistically analyzed by DNA chip analyzer (dChip) as described below in Statistical analysis section and filtered for fold change threshold, and the genes that changed in response to simulated microgravity by more than 2-fold above or below the static 1g controls with p-values of less than 0.05 were deemed considerable and statistically significant. The number of differentially expressed genes and false discovery rate (FDR) were calculated for each of 500 permutations, and 1,934 genes had p-values less than 0.05 at median FDR. Roughly, half of these genes were false positives. GoMiner software (<http://www.miblab.gatech.edu/gominer>) was

used to sort the genes by biological processes and to assign some of the known functions of each known gene (48).

Statistical analysis—Statistical analysis was performed using the Student's *t*-test for *ALP* enzyme activity experiments. A significance level of $p < 0.05$ was considered statistically significant. The microarray data was analyzed with the dChip, a program based on the Model-Based Expression Index (MBEI) method (49, 50). The raw data were normalized using the invariant set normalization, and the average expression values are represented as model-based expression indices. We used the ‘PM only model’, and the expression values were expressed in log₂ scale. Differential gene expression between two groups of samples was analyzed by t-test built in dChip.

Acknowledgements

We would like to thank Drs. Jay McDonald and Majd Zayzafoon for help with the microbead culture methods and Xu Cao at the University of Alabama at Birmingham for the 2T3 cells. Additionally, we wish to thank Kamal Emami from NASA Johnson Space Center for his assistance in growing cells on microcarriers. From the Baylor Microarray Core Facility, we thank Laura Liles for her work on the RWV microarray. We also thank Amy Mowbray, Kyung Hwa Chang, Hannah Song, and Sarah Tressel from Georgia Tech and Emory University for helpful comments during these studies.

References

1. Arbeille, P., Fomina, G., Achaibou, F., Pottier, J. & Kotovskaya, A. (1995) *Acta Astronaut* **36**, 753-62.
2. White, R. & Blomqvist, C. (1998) *J Appl Physiol* **85**, 738-746.
3. Sonnenfeld, G., Butel, J. & Shearer, W. (2003) *Rev Environ Health* **18**, 1-17.
4. Katkovsky BS, P. Y. (1976) *Life Sci Space Res* **14**.
5. Miyamoto, A., Shigematsu, T., Fukunaga, T., Kawakami, K., Mukai, C. & Sekiguchi, C. (1998) *Bone* **22**, 79S-82S.
6. Carmeliet, G. & Bouillon, R. (1999) *FASEB J.* **13**, 129-134.
7. Wang, E. (1999) *FASEB J.* **13 Suppl**, S167-S174.
8. Klement, B. J. & Spooner, B. S. (1999) *Bone* **24**, 349-359.
9. Lang, T., LeBlanc, A., Evans, H., Lu, Y., Genant, H. & Yu, A. (2004) *J Bone Miner Res* **19**, 1006-12.
10. Hughes-Fulford, M. (2004) *Science STKE* **12**.
11. Collet, P., Uebelhart, D., Vico, L., Moro, L., Hartmann, D., Roth, M. & C, A. (1997) *Bone* **20**, 547-551.
12. Caillot-Augusseau, A., Vico, L., Heer, M., Voroviev, D., Souberbielle, J.-C., Zitterman, A., Alexandre, C. & Lafage-Proust, M.-H. (2000) *Clin Chem* **46**, 1136-1143.
13. Caillot-Augusseau, A., Lafage-Proust, M.-H., Soler, C., Pernod, J., Dubois, F. & Alexandre, C. (1998) *Clin Chem* **44**, 578-585.
14. Smith, S., Wastney, M., O'Brien, K., Morukov, B., Larina, I., Abrams, S., Davis-Street, J., Oganov, V. & Shackelford, L. (2005) *J Bone Miner Res* **20**, 208-18.
15. Vermeer, C., Wolf, J., Craciun, A. & Knapen, M. (1998) *J Gravit Physiol* **5**, 65-69.
16. Heer, M., Kamps, N., Biener, C., Korr, C., Boerger, A., Zittermann, A., Stehle, P. & Drummer, C. (1999) *Eur J Med Res* **4**, 657-60.
17. Ontiveros, C., Irwin, R., RW & McCabe, L. (2004) *J Cell Physiology* **200**, 169-76.
18. Klement, B., Young, Q., George, B. & Nokkaew, M. (2004) *Bone* **34**, 487-98.
19. Hoson, T. (1997) *Planta* **203**, S187-197.
20. Pardo, S. J., Patel, M. J., Sykes, M. C., Platt, M. O., Boyd, N. L., Sorescu, G. P., Xu, M., van Loon, J. J. W. A., Wang, M. D. & Jo, H. (2005) *Am J Physiol Cell Physiol* **288**, C1211-1221.
21. Hejnowicz, Z., Sondag, C., Alt, W. & Sievers, A. (1998) *Plant Cell Environ* **21**, 1293-1300.
22. Villa, A., Versari, S., Maier, J. A. & Bradamante, S. (2005) *Gravit Space Biol Bull* **18**, 89-90.
23. Xing, W., Baylink, D., Kesavan, C., Hu, Y., Kapoor, S., Chadwick, R. B. & Mohan, S. (2005) *Journal of Cellular Biochemistry* **9999**, n/a.
24. Tasheva, E. (2002) *Molecular Vision* **8**, 407-15.
25. Buchaille, R., Couble, M. L., Magloire, H. & Bleicher, F. (2000) *Bone* **27**, 265-70.
26. Wadhwa, S., Embree, M. C., Kilts, T., Young, M. F. & Ameye, L. G. (2005) *Osteoarthritis Cartilage* **13**, 817-27.
27. Li, G. (2005) *Calcified Tissue International* **76**, 299-36.
28. Lehmann, W. (2004) *Bone* **35**, 1247-55.
29. Tare, R. (2002) *Journal of Bone and Mineral Research* **17**, 2009-20.

30. Choi, S. J., Reddy, S. V., Devlin, R. D., Menea, C., Chung, H., Boyce, B. F. & Roodman, G. D. (1999) *J Biol Chem* **274**, 27747-53.
31. Funaba, M., Murata, T., Murata, E., Ogawa, K., Abe, M., Takahashi, M. & Torii, K. (1997) *Life Sci* **61**, 653-8.
32. Rucci, N., Migliaccio, S., Zani, B. M., Taranta, A. & Teti, A. (2002) *J Cell Biochem* **85**, 167-79.
33. Komori, T., Yagi, H., Nomura, S., Yamaguchi, A., Sasaki, K., Deguchi, K., Shimizu, Y., Bronson, R. T., Gao, Y. H., Inada, M., Sato, M., Okamoto, R., Kitamura, Y., Yoshiki, S. & Kishimoto, T. (1997) *Cell* **89**, 755-64.
34. Katagiri, T. & Takahashi, N. (2002) *Oral Dis* **8**, 147-59.
35. Loughlin, J. (2005) *Curr Opin Rheumatol* **17**, 629-33.
36. Lorenzo, P., Aspberg, A., Onnerfjord, P., Bayliss, M. T., Neame, P. J. & Heinegard, D. (2001) *J. Biol. Chem.* **276**, 12201-12211.
37. Bengtsson, E., Morgelin, M., Sasaki, T., Timpl, R., Heinegard, D. & Aspberg, A. (2002) *J Biol Chem* **277**, 15061-8.
38. Torday, J. S. (2003) *Adv Space Res* **32**, 1569-76.
39. Wijgerde, M., Karp, S., McMahon, J. & McMahon, A. P. (2005) *Dev Biol* **286**, 149-57.
40. Tsumaki, N., Nakase, T., Miyaji, T., Kakiuchi, M., Kimura, T., Ochi, T. & Yoshikawa, H. (2002) *J Bone Miner Res* **17**, 898-906.
41. Li, B., Ishii, T., Tan, C. P., Soh, J. W. & Goff, S. P. (2002) *J Biol Chem* **277**, 12418-22.
42. Kawai, S., Takeshita, S., Okazaki, M., Kikuno, R., Kudo, A. & Amann, E. (1994) *J Biochem (Tokyo)* **115**, 641-3.
43. Lin, J. T. & Lane, J. M. (2004) *Clin Orthop Relat Res*, 126-34.
44. Parfitt, A. M. (1987) *Clin Obstet Gynecol* **30**, 789-811.
45. Schwarz, R. P., Goodwin, T. J. & Wolf, D. A. (1992) *J Tissue Cult Methods* **14**, 51-7.
46. Boo, Y. C., Sorescu, G., Boyd, N., Shiojima, I., Walsh, K., Du, J. & Jo, H. (2002) *J Biol Chem* **277**, 3388-96.
47. Sorescu, G. P., Sykes, M., Weiss, D., Platt, M. O., Saha, A., Hwang, J., Boyd, N., Boo, Y. C., Vega, J. D., Taylor, W. R. & Jo, H. (2003) *J. Biol. Chem.* **278**, 31128-31135.
48. Zeeberg, B., Feng, W., Wang, G., Wang, M., Fojo, A., Sunshine, M., Narasimhan, S., Kane, D., Reinhold, W., Lababidi, S., Bussey, K., Riss, J., Barrett, J. & Weinstein, J. (2003) *Genome Biology* **4**, R28.
49. Li, C. & Wong, W. H. (2001) *PNAS* **98**, 31-36.
50. Li, C. & Wong, W. H. (2001) *Genome Biology* **2**, research0032.1 - research0032.11.
51. Wang, Y., Yang, S. X., Tu, P., Zhang, B. & Ma, S. Q. (2002) *J Dermatol Sci* **30**, 136-41.

Figure Legend

Figure 1. RWV exposure inhibits alkaline phosphatase activity and mRNA expression in

2T3 cells. Confluent 2T3 cells grown on microcarriers were placed in the RWV for 3 days of rotation or incubated in T-75 flasks for static 1g controls for the same period. The alkaline phosphatase activity (A) was determined by a colorimetric assay using cell lysates and *alkaline phosphatase (ALP)* mRNA levels (B) determined by real time PCR with 18S as an internal control. The graphs show mean \pm SEM (* $p < 0.05$, $n = 6$ for A and $n = 3$ for B).

Figure 2. The effects of RWV-simulated microgravity on gene transcript profiles of 2T3

cells as determined by Affymetrix microarray analysis. Total RNA was isolated from 2T3 cells exposed to RWV or static 1g controls for 3 days. cRNA was then prepared and analyzed by Affymetrix microarrays corresponding to 40,000 mouse genes. The scatter plot shows mean intensities of each gene probe using the data obtained from all microarrays. Statistical analysis identified 66 genes upregulated (red dots) and 45 genes downregulated (green dots) by more than 2-fold compared to static 1g control ($p < 0.05$, $n = 3$). Unchanged genes are shown in black in the scatter plot.

Figure 3. Verification of microarray results by real time PCR and Western blot for genes

that were upregulated or downregulated by RWV exposure of 2T3 cells. Aliquots of total RNA used for microarray studies ($n = 3$, simulated μg and static 1g) were used for the quantitative real time PCR assay for *Runx2* (A), *BMP4* (B), *PthR1* (C) and *osteomodulin (OMD)* (D) using 18S rRNA as internal controls. Additional experiments were performed to obtain cell lysates for the Western blot assay using antibodies specific to BMP4 (F), peroxiredoxin IV (Prx IV, G),

osteoglycin (Ogn, H), and Prx I (I) using β -actin as an internal control. Error bars shown represent mean \pm SEM ($n \geq 3$, * $p < 0.05$). Comparison of the Affymetrix microarray fold changes to the quantitative RT-PCR (E) or Western blot results (J).

Figure 4. Simulated microgravity using the RWV and the RPM. A. The Rotating Wall Vessel (RWV) bioreactor is a one-dimensional clinostat that simulates microgravity conditions by maintaining particles in a free-fall state. B. The Random Positioning Machine (RPM) is a three-dimensional clinostat that simulates microgravity by continuously rotating the cells in a random orientation at random speeds. Both simulators use the gravity vector averaging method to simulate microgravity.

Table 1 A list of selected statistically significant genes sensitive to RWV simulated microgravity in 2T3 cells. Sorted based on typical biological process (p<0.05).

| Accession # | Gene Name | *Fold Δ | p-value | Molecular Function |
|-----------------------------|---|---------|---------|---|
| Cell Adhesion | | | | |
| NM_012050 | <i>osteomodulin</i> | 0.10 | 0.04 | aka osteoadherin, may mediate cell attachment |
| NM_011581 | <i>thrombospondin 2</i> | 0.39 | 0.03 | structural molecule activity; calcium ion binding |
| BB781435 | <i>nidogen 2</i> | 0.39 | 0.004 | calcium ion binding |
| NM_007729 | <i>procollagen, type XI, alpha 1</i> | 0.40 | 0.04 | extracellular matrix structural constituent |
| NM_012043 | <i>immunoglobulin superfamily containing leucine rich repeat (ISLR)</i> | 0.42 | 0.02 | involved in cell attachment |
| BB250384 L08431 | <i>vascular cell adhesion molecule 1</i> | 0.45 | 0.02 | protein binding |
| BF225985 | <i>discoidin domain receptor family, member 1</i> | 0.49 | 0.04 | protein kinase activity; protein serine/threonine kinase activity |
| BC013560 | <i>procollagen, type IV, alpha 2</i> | 2.02 | 0.03 | structural molecule activity; extracellular matrix structural constituent |
| BG073728 | <i>RGM domain family, member B</i> | 2.24 | 0.05 | protein self binding |
| BM935811 | <i>integrin alpha 6</i> | 2.47 | 0.01 | receptor activity; protein binding |
| BF158638 | <i>procollagen, type IV, alpha 1</i> | 2.59 | 0.002 | structural molecule activity; extracellular matrix structural constituent |
| Cell Cycle | | | | |
| NM_011817 AK007410 | <i>growth arrest and DNA damage inducible, gamma</i> | 0.40 | 0.009 | structural constituent of ribosome |
| AK004608 | <i>heat shock protein 8</i> | 2.27 | 0.04 | protein binding; ATP binding |
| Cell Differentiation | | | | |
| NM_025711 | <i>asporin</i> | 0.15 | 0.05 | porin activity; cartilage extracellular protein |
| Development | | | | |
| NM_031258 | <i>chordin-like 1</i> | 0.16 | 0.03 | unknown |
| NM_009144 | <i>secreted frizzled-related sequence protein 2</i> | 0.43 | 0.03 | transmembrane receptor and signal transduction activity |
| BB549310 | <i>olfactomedin 1</i> | 2.66 | 0.02 | unknown |
| Skeletal Development | | | | |
| NM_007554 | <i>bone morphogenetic protein 4</i> | 0.40 | 0.002 | cytokine activity |
| NM_054077 | <i>proline arginine-rich end leucine-rich repeat</i> | 0.43 | 0.05 | extracellular matrix structural constituent |
| NM_011641 | <i>transformation related protein 63</i> | 0.47 | 0.04 | DNA binding; transcription factor activity |
| Cell Growth | | | | |
| NM_010516 | <i>cysteine rich protein 61</i> | 0.24 | 0.02 | protein binding; insulin-like growth factor binding |

| Accession # | Gene Name | *Fold Δ | p-value | Molecular Function |
|--------------------------------|---|---------|---------|---|
| NM_016873 | <i>WNT1 inducible signaling pathway protein 2</i> | 0.39 | 0.01 | phospholipase A2 activity; calcium ion binding |
| BC020038 | <i>endothelial cell-specific molecule 1</i> | 0.46 | 0.01 | insulin-like growth factor binding |
| Cytoskeletal Regulation | | | | |
| NM_008857 | <i>protein kinase C, iota</i> | 0.45 | 0.04 | actin filament organization |
| AV297945 | <i>myosin X</i> | 0.46 | 0.046 | motor activity; actin binding |
| AW491660 | <i>tubulin, alpha 4</i> | 2.42 | 0.007 | microtubule based movement; GTPase activity; structural molecule activity |
| Metabolism | | | | |
| NM_007934 | <i>glutamyl aminopeptidase</i> | 0.40 | 0.03 | DNA binding; protein binding |
| AY057913 | <i>brain derived neurotrophic factor</i> | 0.46 | 0.02 | mechanoreceptor differentiation; protein binding; growth factor activity |
| NM_007436 | <i>aldehyde dehydrogenase family 3, subfamily A1</i> | 2.56 | 0.04 | aldehyde dehydrogenase activity |
| Proteolysis | | | | |
| NM_011269 | <i>Rhesus blood group-associated A glycoprotein</i> | 0.36 | 0.01 | cysteine-type endopeptidase activity |
| AF282844 | <i>matrix metalloproteinase 16</i> | 0.47 | 0.04 | metalloendopeptidase activity |
| BB658835 | <i>a disintegrin-like and metalloprotease (repolyisin type) with thrombospondin type 1 motif, 5 (aggrecanase-2)</i> | 0.48 | 0.03 | metalloendopeptidase activity; peptidase activity |
| AK011596 | <i>transferrin receptor</i> | 2.40 | 0.05 | receptor activity; transferrin receptor activity |
| Signal Transduction | | | | |
| NM_008046 | <i>follistatin</i> | 0.39 | 0.02 | BMP signaling pathway |
| Protein Folding | | | | |
| NM_013560 | <i>heat shock protein 1</i> | 2.03 | 0.04 | unknown |
| NM_011020 | <i>heat shock 70kDa protein 4 like</i> | 2.06 | 0.02 | ATP binding; unfolded protein binding |
| Transport | | | | |
| AK018504 | <i>ras association (RalGDS/AF-6) domain family 2</i> | 0.43 | 0.27 | protein binding |
| AV344473 | <i>sorting nexin associated golgi protein 1</i> | 0.48 | 0.008 | unknown |
| BB280137 | <i>RAB guanine nucleotide exchange factor (GEF) 1</i> | 0.48 | 0.02 | DNA binding; zinc ion binding |
| BB144704 | <i>ATP-binding cassette, sub-family A (ABC1), member 1</i> | 0.48 | 0.02 | ATP binding; ATPase activity |
| Chromosome Organization | | | | |
| BB533903 | <i>histone 1, H1c</i> | 0.29 | 0.03 | DNA binding; protein binding |
| M25487 NM_023422 | <i>histone 1, H2bc</i> | 0.44 | 0.03 | DNA binding |

| Accession # | Gene Name | *Fold Δ | p-value | Molecular Function |
|---|--|---------|---------|--|
| Nitric Oxide Synthesis | | | | |
| BF166000 | <i>high mobility group box 1</i> | 0.41 | 0.04 | nitric-oxide synthase regulator activity |
| Multidrug Transport | | | | |
| BB291885 | <i>ATP-binding cassette, sub-family C (CFTR/MRP), member 4</i> | 2.35 | 0.003 | multidrug efflux pump activity |
| Endocytosis | | | | |
| AI848122 | <i>low density lipoprotein receptor-related protein 8, apolipoprotein e receptor</i> | 2.30 | 0.04 | receptor activity; calcium ion binding |
| Stress or Immune Response | | | | |
| NM_007705 | <i>cold inducible RNA binding protein</i> | 0.21 | 0.003 | |
| D67017 | <i>heat shock protein 105</i> | 2.54 | 0.02 | protein binding; ATP binding |
| AW763765 | <i>heat shock protein 1A</i> | 3.18 | 0.04 | ATP binding |
| Regulation of Cell Growth | | | | |
| NM_008760 | <i>osteoglycin</i> | 0.23 | 0.03 | growth factor activity |
| Negative Regulation of Cell Growth | | | | |
| NM_009517 | <i>wild-type p53-induced gene 1</i> | 2.18 | 0.03 | unknown |
| Unknown | | | | |
| BC002065 | <i>serine (or cysteine) proteinase inhibitor, clade A, member 3G</i> | 0.35 | 0.02 | endopeptidase inhibitor activity |
| NM_133859 | <i>olfactomedin-like 3</i> | 0.40 | 0.02 | unknown |
| NM_016753 | <i>latexin</i> | 0.44 | 0.01 | enzyme inhibitor activity; metalloendopeptidase inhibitor activity |
| NM_007984 | <i>fascin homolog 1, actin bundling protein</i> | 0.47 | 0.04 | actin binding; actin filament binding |
| NM_029632 | <i>protein phosphatase 1, regulatory (inhibitor) subunit 11</i> | 2.17 | 0.03 | unknown |
| AI266910 | <i>ceroid-lipofuscinosis, neuronal 2</i> | 2.07 | 0.04 | serine-type endopeptidase activity |
| NM_009266 | <i>selenophosphate synthetase 2</i> | 2.02 | 0.004 | catalytic activity |

* Fold=simulated microgravity expression/static 1g expression

Table 2 The effect of microgravity on selected genes that may be involved in osteoblast differentiation and matrix mineralization. Sorted based on fold changes.

| Accession # | Gene Name | *Fold Δ | p-value | Molecular Function |
|-------------|---|---------|---------|--|
| NM_012050 | <i>osteomodulin</i> | 0.10 | <0.05 | aka osteoadherin, may mediate cell attachment |
| NM_008760 | <i>osteoglycin</i> | 0.23 | <0.05 | binds to TGF-beta, no GAG in bone, keratan sulfate in other tissues |
| NM_025711 | <i>asporin</i> | 0.28 | <0.05 | porin activity; cartilage extracellular protein |
| BG229308 | <i>procollagen, type VIII, alpha 2</i> | 0.35 | >0.1 | present in cartilage |
| BC002065 | <i>serine (or cysteine) proteinase inhibitor, clade A, member 3G</i> | 0.35 | <0.05 | may be involved in osteoclast function with MMPs and cathepsins |
| NM_007729 | <i>procollagen, type XI, alpha 1</i> | 0.37 | <0.05 | present in cartilage |
| NM_011581 | <i>thrombospondin 2</i> | 0.39 | <0.025 | involved in cell attachment |
| NM_016873 | <i>WNT1 inducible signaling pathway protein 2</i> | 0.39 | <0.05 | involved in WNT pathway, WNT stimulated by BMPs |
| BB781435 | <i>nidogen 2</i> | 0.39 | <0.005 | calcium binding |
| NM_007554 | <i>bone morphogenetic protein 4</i> | 0.40 | <0.0025 | growth factor and cytokine activity |
| BM218630 | <i>protocadherin 18</i> | 0.40 | >0.05 | calcium ion binding |
| NM_011693 | <i>vascular cell adhesion molecule 1</i> | 0.41 | <0.025 | cell adhesion molecule activity |
| BB396904 | <i>calmodulin 3</i> | 0.41 | >0.1 | calcium binding; regulates osteoclast differentiation |
| NM_012043 | <i>immunoglobulin superfamily containing leucine rich repeat (ISLR)</i> | 0.42 | <0.05 | involved in cell attachment |
| NM_009144 | <i>secreted frizzled-related sequence protein 2</i> | 0.43 | <0.05 | WNT signaling pathway antagonist |
| BC002064 | <i>pleiotrophin</i> | 0.43 | >0.1 | involved in bone mineralization |
| NM_009821 | <i>runt related transcription factor 1</i> | 0.43 | >0.1 | mesenchymal cell differentiation |
| BI111620 | <i>tissue inhibitor of metalloproteinase 3</i> | 0.44 | >0.1 | may be involved in bone resorption |
| NM_021355 | <i>fibromodulin</i> | 0.45 | >0.05 | binds to collagen, may regulate fibril formation, binds to TGF-beta |
| BB431535 | <i>matrix metalloproteinase 16</i> | 0.47 | <0.05 | involved in osteoclast function and bone resorption |
| M93954 | <i>tissue inhibitor of metalloproteinase 2</i> | 0.48 | >0.1 | involved in bone resorption |
| AW412729 | <i>procollagen, type XII, alpha 1</i> | 0.48 | >0.05 | present in collagen; extracellular matrix structural constituent |
| C76813 | <i>a disintegrin and metalloproteinase domain 17</i> | 0.48 | >0.1 | involved in matrix protein degradation; prevent osteoclast recruitment |
| BB371406 | <i>frizzled homolog 2 (Drosophila)</i> | 0.48 | >0.1 | involved in WNT pathway |
| NM_009933 | <i>procollagen, type VI, alpha 1</i> | 0.49 | <0.1 | present in cartilage |
| AU021035 | <i>syndecan 2</i> | 0.50 | >0.1 | binds to type 1 collagen, fibronectin, tenascin-C |
| AA717838 | <i>interleukin 6 signal transducer</i> | 0.50 | >0.1 | act as stimulators of an early stage of osteoclast formation |
| BF580235 | <i>cathepsin E</i> | 0.50 | >0.1 | involved in bone resorption |
| NM_010511 | <i>interferon gamma receptor 1</i> | 0.52 | >0.05 | inhibit bone resorption |
| BE628614 | <i>annexin A4</i> | 0.52 | >0.1 | expressed in osteoblasts and relocation dependent on calcium |
| BF537076 | <i>interferon gamma receptor 2</i> | 0.53 | >0.1 | inhibit bone resorption |

| Accession # | Gene Name | Fold Δ | p-value | Molecular Function |
|-------------|---|--------|---------|---|
| AF153440 | <i>BMP and activin membrane-bound inhibitor, homolog (Xenopus laevis)</i> | 0.53 | >0.05 | antagonist to BMPs; involved in TGF-beta signaling pathway |
| NM_011199 | <i>parathyroid hormone receptor 1</i> | 0.54 | >0.1 | transmembrane receptor activity |
| NM_009627 | <i>adrenomedullin</i> | 0.57 | >0.1 | neuropeptide hormone activity |
| AI385532 | <i>thrombospondin 1</i> | 0.59 | >0.1 | involved in cell attachment |
| BC014690 | <i>transforming growth factor, beta 3</i> | 0.59 | <0.05 | growth factor and cytokine activity |
| NM_011580 | <i>thrombospondin 1</i> | 0.59 | >0.1 | cell attachment |
| NM_007743 | <i>procollagen, type I, alpha 2</i> | 0.62 | >0.1 | the major constituent of bone matrix |
| BG248060 | <i>bone morphogenetic protein 1</i> | 0.62 | >0.1 | metalloendopeptidase activity |
| NM_007737 | <i>procollagen, type V, alpha 2</i> | 0.68 | >0.1 | present where there is collagen type I |
| AF053954 | <i>cbfa1/runx2 (osf2)</i> | 0.69 | >0.05 | essential transcription factor for osteoblast differentiation and bone formation |
| BB730912 | <i>interleukin 13 receptor, alpha 1</i> | 0.69 | >0.1 | inhibit bone resorption |
| NM_020273 | <i>glucocorticoid modulatory element binding protein 1</i> | 0.70 | >0.05 | transcription factor activity |
| S80963 | <i>interleukin 13 receptor, alpha 1</i> | 0.72 | >0.1 | inhibit bone resorption |
| NM_019444 | <i>RAMP2</i> | 0.73 | >0.1 | calcitonin signal transducer activity |
| NM_008216 | <i>hyaluronan synthase 2</i> | 0.74 | <0.05 | with versican-like protein works to captures space destined to become bone |
| NM_007833 | <i>decorin</i> | 0.76 | <0.025 | binds to collagen and may regulate fibril diameter |
| NM_007431 | <i>alkaline phosphatase 2, liver</i> | 0.82 | <0.05 | essential for hydroxyapatite formation and matrix mineralization |
| BB082407 | <i>hyaluronan and proteoglycan link protein 4</i> | 1.22 | <0.05 | present in articular cartilage |
| BM251152 | <i>chondroitin sulfate proteoglycan 2</i> | 1.23 | >0.05 | present in cartilage |
| NM_009758 | <i>bone morphogenetic protein receptor, type 1A</i> | 1.37 | >0.1 | TGF-β and BMP receptor |
| BG092290 | <i>insulin-like growth factor 2 receptor</i> | 1.43 | <0.025 | signal transduction and hormone activity |
| NM_007802 | <i>cathepsin K</i> | 1.43 | >0.1 | may regulate elastic fiber formation (calcium ion binding activity) |
| NM_020275 | <i>tumor necrosis factor receptor superfamily, member 10b</i> | 1.43 | <0.05 | growth factor and cytokine activity |
| NM_008965 | <i>prostaglandin E receptor 4</i> | 1.45 | >0.1 | G-protein coupled receptor activity |
| BG069059 | <i>leucine rich repeat (in FLII) interacting protein 1</i> | 1.52 | >0.05 | leucine rich repeats involved in bone mineralization |
| NM_010554 | <i>interleukin 1a</i> | 1.58 | <0.05 | potent stimulators of bone resorption |
| NM_011361 | <i>serum/glucocorticoid regulated kinase</i> | 1.65 | >0.05 | transferase activity, transferring phosphorus-containing groups |
| M94967 | <i>prostaglandin-endoperoxide synthase 2</i> | 2.05 | >0.05 | prostaglandins important in fluid shear over bone cells |
| BM935811 | <i>integrin α6</i> | 2.47 | <0.05 | cell adhesion molecule |
| AK003744 | <i>cystatin E/M</i> | 3.45 | <0.05 | antagonist to cathepsin family |
| NM_011111 | <i>serine (or cysteine) proteinase inhibitor, clade B, member 2</i> | 7.14 | >0.05 | may be involved in osteoclast function with MMPs and cathepsins |
| X75557 | <i>proliferin</i> | 14.4 | >0.05 | involved in cell adhesion; may regulate cathepsin L; involved in cell proliferation |

* Fold=simulated microgravity expression/static expression

Table 3 A list of statistically significant common genes sensitive to simulated microgravity in 2T3 cells using both RPM and RWV. Sorted based on typical biological process (p<0.05).

| Accession # | Gene Name | *Fold Δ RWV | *Fold Δ RPM | Molecular Function |
|----------------------------------|--|-------------|-------------|---|
| Cell Adhesion | | | | |
| NM_012050 | <i>osteomodulin</i> | 0.10 | 0.18 | aka osteoadherin, may mediate cell attachment |
| NM_007729 | <i>procollagen, type XI, alpha 1</i> | 0.37 | 0.29 | extracellular matrix structural constituent |
| NM_012043 | <i>immunoglobulin superfamily containing leucine rich repeat</i> | 0.18 | 0.42 | involved in cell attachment |
| AK004179 | <i>platelet-derived growth factor receptor-like</i> | 0.45 | 0.52 | involved in cell attachment and possibly cell proliferation |
| Cell Cycle | | | | |
| NM_011817 | <i>growth arrest and DNA damage inducible, gamma</i> | 0.40 | 0.49 | structural constituent of ribosome |
| Development | | | | |
| NM_009144 | <i>secreted frizzled-related sequence protein 2</i> | 0.43 | 0.41 | transmembrane receptor and signal transduction activity |
| Regulation of Cell Growth | | | | |
| NM_030127 | <i>serine protease</i> | 0.74 | 0.22 | serine-type endopeptidase activity |
| NM_008760 | <i>osteoglycin</i> | 0.23 | 0.38 | growth factor activity |
| Protein Biosynthesis | | | | |
| NM_026631 | <i>nucleolar protein family A, member 2</i> | 1.69 | 2.04 | RNA binding; structural constituent of ribosome |
| Transport | | | | |
| AK018504 | <i>ras association (RalGDS/AF-6) domain family 2</i> | 0.27 | 0.43 | protein binding |
| Cell Differentiation | | | | |
| NM_025711 | <i>asporin</i> | 0.15 | 0.28 | porin activity; cartilage extracellular protein |
| Metabolism | | | | |
| NM_007934 | <i>glutamyl aminopeptidase</i> | 0.40 | 0.35 | aminopeptidase activity |
| Skeletal Development | | | | |
| NM_054077 | <i>proline arginine rich end leucine rich repeat</i> | 0.43 | 0.45 | extracellular matrix structural constituent |
| Unknown | | | | |
| NM_021355 | <i>fibromodulin</i> | 0.45 | 0.45 | unknown |

* Fold=simulated microgravity expression/static expression

Table 4 Comparison of gene expression changes among RWV, RPM, and mechanical load microarrays. Sorted by biological process.

| Accession # | Gene Name | Fold Δ RWV | p-value RWV | Fold Δ RPM | p-value RPM | Fold Δ <i>in vivo</i> | p-value <i>in vivo</i> | Molecular Function |
|--|--|------------|-------------|------------|-------------|-----------------------|------------------------|--|
| Cell Growth & Differentiation | | | | | | | | |
| AK014259 | <i>osteoglycin</i> | 0.22 | p<0.05 | 0.38 | p<0.005 | 2.47 | p<0.005 | binds to TGF-Beta |
| NM_008409 | <i>integral membrane protein 2A</i> | 0.31 | p>0.1 | 0.53 | p<0.05 | 2.85 | p<0.005 | marker gene of osteoblastic cells in bone formation |
| NM_007792 | <i>cysteine and glycine-rich protein 2</i> | 0.65 | p<0.05 | 0.68 | p>0.1 | 4.12 | p<0.0025 | zinc ion binding |
| AK011346 | <i>pleiotrophin</i> | 0.43 | p>0.1 | 0.36 | p<0.05 | 4.29 | p<0.0025 | involved in bone mineralization; growth factor binding |
| Cell Adhesion | | | | | | | | |
| NM_015734 | <i>procollagen, type V, alpha 1</i> | 0.56 | p>0.05 | 0.65 | p>0.1 | 1.97 | p<0.0025 | present in cartilage ECM |
| NM_007739 | <i>procollagen, type VIII, alpha 1</i> | 0.57 | p>0.05 | 0.68 | p>0.1 | 2.56 | p<0.0025 | present in cartilage ECM |
| Cell Death | | | | | | | | |
| NM_008086 | <i>growth arrest specific 1</i> | 0.59 | p>0.1 | 0.53 | p<0.01 | 2.26 | p<0.0025 | protein binding |
| Proteolysis | | | | | | | | |
| NM_008788 | <i>procollagen C-proteinase enhancer protein</i> | 0.56 | p<0.01 | 0.52 | p<0.05 | 2.15 | p<0.005 | nucleic acid binding |
| NM_011175 | <i>legumain</i> | 0.64 | p>0.1 | 0.66 | p>0.05 | 3.25 | p<0.005 | cysteine-type endopeptidase activity |
| Signal Transduction | | | | | | | | |
| NM_008809 | <i>platelet derived growth factor receptor, beta polypeptide</i> | 0.74 | p>0.1 | 0.61 | p>0.05 | 1.97 | p<0.01 | protein serine/threonine kinase activity |
| NM_009037 | <i>reticulocalbin</i> | 0.69 | p<0.05 | 0.85 | p>0.1 | 2.31 | p<0.005 | calcium ion binding |
| Transcription regulation | | | | | | | | |
| NM_010351 | <i>goosecoid</i> | 0.58 | p>0.1 | 0.68 | p>0.1 | 2.3 | p<0.005 | DNA binding |
| NM_019791 | <i>melanoma antigen, family D, 1</i> | 0.54 | p>0.1 | 0.55 | p<0.005 | 2.33 | p<0.0025 | transcription coactivator activity |
| Cytoskeletal Movement | | | | | | | | |
| NM_007392 | <i>actin, alpha 2, smooth muscle, aorta</i> | 0.64 | p>0.1 | 0.85 | p>0.1 | 1.97 | p<0.0025 | structural constituent of cytoskeleton |
| Other | | | | | | | | |
| NM_009128 | <i>stearoyl-coenzyme A desaturase 2</i> | 0.4 | p>0.1 | 0.35 | p<0.0025 | 2.56 | p<0.0025 | iron ion binding |
| AK004179 | <i>platelet-derived growth factor receptor-like</i> | 0.45 | p<0.005 | 0.52 | p<0.05 | 2.18 | p<0.005 | receptor activity |

Table 5 Primers and LightCycler conditions used for Real-Time PCR

| GeneBank Accession No. | Gene | Primers (5'-3') | | bp | LightCycler Conditions | Ref. |
|---------------------------|--------------|-----------------|-------------------------------|-----|---------------------------|------|
| NM_009820 | <i>Runx2</i> | Fw | GACAGAAGCTTGATGACTCTAAACC | 171 | 7 sec; 62°C | (17) |
| | | Rv | TCTGTAATCTGACTCTGTCCTTGT | | 9 sec; 72°C | |
| NM_007554 | <i>BMP4</i> | Fw | CTGCGGGACTTCGAGGCGACACTTCT | 150 | 7 sec; 65°C | (47) |
| | | Rv | TCTTCCTCCTCCTCCTCCCCAGACTG | | 7 sec; 72°C | |
| NM_011199 | <i>PthR1</i> | Fw | GCACACAGCAGCCAACATAA | 531 | 7 sec at 63°C | (51) |
| | | Rv | CGCAGCCTAAACGACAGGAA | | 22 sec at 72°C | |
| NM_012050 | <i>Omd</i> | Fw | GACGGGCTGGTGAATGTGACTATGCTTGA | 147 | 7 sec; 63°C | (20) |
| | | Rv | CCAAGGGGCATTGATTCTAATCTGTTATT | | 10 sec; 72°C | |